Madrigal Pharmaceuticals, Inc.
MDGL
$546.66
$12.502.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -57.94M | -94.39M | -58.58M | -114.19M | -42.28M |
| Total Depreciation and Amortization | 1.03M | 794.00K | 1.94M | 1.91M | 432.00K |
| Total Amortization of Deferred Charges | 464.00K | 449.00K | 468.00K | 329.00K | 371.00K |
| Total Other Non-Cash Items | 46.36M | 31.58M | 25.18M | 28.70M | 26.10M |
| Change in Net Operating Assets | 33.42M | -105.87M | -102.47M | 163.10M | -31.68M |
| Cash from Operations | 23.33M | -167.44M | -133.46M | 79.85M | -47.05M |
| Capital Expenditure | -4.25M | -3.85M | 390.00K | -857.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 38.45M | 196.04M | 27.19M | -206.14M | 47.86M |
| Cash from Investing | 34.20M | 192.19M | 27.58M | -207.00M | 47.86M |
| Total Debt Issued | -- | -- | 0.00 | 350.00M | -- |
| Total Debt Repaid | -- | -- | 0.00 | -121.66M | -- |
| Issuance of Common Stock | 3.11M | 2.33M | 9.94M | 17.74M | 1.74M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -983.00K | -9.42M | -- |
| Cash from Financing | 3.11M | 2.33M | 8.96M | 236.65M | 1.74M |
| Foreign Exchange rate Adjustments | 57.00K | 1.32M | 13.00K | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.69M | 28.41M | -96.91M | 109.50M | 2.55M |